Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course

Saroj S. Bakshi, Linqi Zhang, David Ho, Soe Than, Savita G Pahwa

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.

Original languageEnglish
Pages (from-to)38-40
Number of pages3
JournalClinical and Diagnostic Laboratory Immunology
Volume5
Issue number1
StatePublished - Jan 1 1998
Externally publishedYes

Fingerprint

Viruses
HIV
Tropics
Macrophages
Centers for Disease Control and Prevention (U.S.)
Infection
Disease Progression
HIV-1
Genes
Mutation
Survival
Population

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Immunology
  • Immunology and Allergy
  • Microbiology (medical)

Cite this

Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course. / Bakshi, Saroj S.; Zhang, Linqi; Ho, David; Than, Soe; Pahwa, Savita G.

In: Clinical and Diagnostic Laboratory Immunology, Vol. 5, No. 1, 01.01.1998, p. 38-40.

Research output: Contribution to journalArticle

@article{f080a56777ec45af9d15c5faba3b1d40,
title = "Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course",
abstract = "Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8{\%} of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.",
author = "Bakshi, {Saroj S.} and Linqi Zhang and David Ho and Soe Than and Pahwa, {Savita G}",
year = "1998",
month = "1",
day = "1",
language = "English",
volume = "5",
pages = "38--40",
journal = "Clinical and Vaccine Immunology",
issn = "1556-6811",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Distribution of CCR5δ32 in human immunodeficiency virus-infected children and its relationship to disease course

AU - Bakshi, Saroj S.

AU - Zhang, Linqi

AU - Ho, David

AU - Than, Soe

AU - Pahwa, Savita G

PY - 1998/1/1

Y1 - 1998/1/1

N2 - Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.

AB - Homozygosity for a 32-bp deletion in the CCR5 gene (CCRSΔ32) has been shown to confer resistance to infection with the macrophage-tropic strain of human immunodeficiency virus (HIV) type 1. We examined the distribution of CCRSΔ32 in 47 children (age range, 1.5 to 19 years), of whom 43 were infected with HIV, by the perinatal route (n = 41) or by the intravenous route (n = 2). The infected patients were classified as rapid progressors (RP) (n = 7) (CDC category C3 or death by 2 years of age), non-rapid progressors (NRP) (n = 17) (survival for ≤8 years after infection), or intermediate (n = 19). CCR5Δ32 heterozygosity was found in two HIV-infected children, both NRP. None of the subjects were homozygous for CCR5Δ32, and the remaining children had no evidence of CCR5Δ32. The presence of CCR5Δ32 heterozygosity in 4.8% of this, predominantly non-Caucasian population is consistent with the published distribution of the mutation. The finding that CCR5Δ32 was present only in NRP and not in any RP is in agreement with previous reports suggesting that heterozygosity for CCR5Δ32 may confer limited protection from disease progression.

UR - http://www.scopus.com/inward/record.url?scp=0031594461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031594461&partnerID=8YFLogxK

M3 - Article

C2 - 9455877

AN - SCOPUS:0031594461

VL - 5

SP - 38

EP - 40

JO - Clinical and Vaccine Immunology

JF - Clinical and Vaccine Immunology

SN - 1556-6811

IS - 1

ER -